METHODS AND COMPOSITIONS FOR DETECTING CANCER
Disclosed herein are methods and composition of improving accuracy of cancer detection and enhancing therapeutic outcomes. The compositions, methods and systems described herein facilitate assessing risk assessment of cancer.
1 . A cancer profiling panel comprising a plurality of polypeptide probes, at least one of which comprises:
(a) a polypeptide probe comprising the full length or epitope fragment of a protein comprising amino acid sequence SEQ ID NO: 23 or encoded by SEQ ID NO: 24;
(b) a polypeptide probe comprising the full length or epitope fragment of a protein comprising amino acid sequence SEQ ID NO: 25 or encoded by SEQ ID NO: 26;
or
(c) a polypeptide probe comprising the full length or epitope fragment of a protein comprising amino acid sequence SEQ ID NO: 27 or encoded by SEQ ID NO: 28.
2 . (canceled)
3 . The cancer profiling panel of claim 1 , comprising two or more polypeptide probes selected from the group consisting of: (a), (b), and (c).
4 . The cancer profiling panel of claim 1 , comprising polypeptide probes (a), (b), and (c).
5 - 15 . (canceled)
16 . The cancer profiling panel of claim 1 , wherein the polypeptide probes are, individually, displayed on a phage.
17 . The cancer profiling panel of claim 16 , wherein the phage is a T7 phage.
18 . The cancer profiling panel claim 1 , wherein the polypeptide probes are configured to be specifically bound by an antibody.
19 . The cancer profiling panel of claim 18 , wherein the antibody is a human antibody.
20 . The cancer profiling panel of claim 19 , wherein the antibody is an autoantibody.
21 . The cancer profiling panel of claim 1 , wherein the polypeptide probes are arranged in an addressable array.
22 . (canceled)
23 . The cancer profiling panel of claim 1 , wherein the polypeptide probes are attached to a bead.
24 . The cancer profiling panel of claim 1 , wherein the polypeptide probes are attached to a man-made substrate.
25 - 30 . (canceled)
31 . A method comprising contacting a sample from a subject with a cancer profiling panel comprising a plurality of polypeptide probes, at least one of which comprises:
(a) a polypeptide probe comprising the full length or epitope fragment of a protein comprising amino acid sequence SEQ ID NO: 23 or encoded by SEQ ID NO: 24;
(b) a polypeptide probe comprising the full length or epitope fragment of a protein comprising amino acid sequence SEQ ID NO: 25 or encoded by SEQ ID NO: 26;
or
(c) a polypeptide probe comprising the full length or epitope fragment of a protein comprising amino acid sequence SEQ ID NO: 27 or encoded by SEQ ID NO: 28;
and
measuring a level of antibodies from the sample bound to the plurality of polypeptide probes.
32 . (canceled)
33 . The method of claim 31 , wherein the cancer profiling panel comprises two or more polypeptide probes selected from the group consisting of: (a), (b), and (c).
34 . The method of claim 31 , wherein the cancer profiling panel comprises polypeptide probes (a), (b), and (c).
35 - 45 . (canceled)
46 . The method of claim 31 , wherein the polypeptide probes are, individually, displayed on a phage.
47 - 48 . (canceled)
49 . The method of claim 31 , wherein the antibodies comprise human antibodies.
50 . The method of claim 49 , wherein the human antibodies comprise autoantibodies.
51 . The method of claim 31 , wherein the polypeptide probes are arranged in an addressable array.
52 . (canceled)
53 . The method of claim 31 , wherein the polypeptide probes are attached to a bead.
54 - 88 . (canceled)
89 . The method of claim 31 , wherein the sample is a blood or serum sample.